The result of the study suggested that the economic model evaluated patients in Canada who were treated with Dabigatran Etexilate compared to those treated with warfarin in both ‘trial-like’ conditions (using the RE-LY trial results) and in a ‘real-world’ clinical practice setting, where patients either received warfarin, aspirin or no treatment.
In the ‘real-world’ clinical practice setting, Dabigatran Etexilate was shown to be particularly cost-effective compared to current care.
RE-LY trial principal investigator Stuart Connolly said they want to do the best for patients and Dabigatran is the medically preferred treatment for stroke prevention.
"From the analyses reported today, we now know that it is cost-effective too – good value to our scarce healthcare budget," Connolly said.